secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2026-08-07T20:04:16+00:00
Accession:  0001339970-26-000051
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr Pharma restructures: 60% workforce cut, CFO change, $58.9M cash, Phase 3 protocol pending FDA
--------------------------------------------------------------------------------

- Workforce reduction of ~60% and annualized opex savings of ~$13M starting Q4 2026.
- CFO Jill Broadfoot steps down Sept 30, 2026; Brandon Yaras becomes CFO Oct 1, 2026.
- Q2 2026 cash $58.9M; runway into late 2028; R&D $6.7M, G&A $4.1M.
- Phase 3 protocol for efzofitimod in pulmonary sarcoidosis submitted to FDA June 2026; feedback expected by end of August 2026.
- Phase 2 EFZO-CONNECT in SSc-ILD enrollment completed; topline results expected Q1 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/0001339970-26-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997026000051/atyr-20260807.htm
  HTML page:      https://secwatch.observer/filing/0001339970-26-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer